- $3.81m
- -$7.20m
- 36
- 54
- 15
- 25
Annual cashflow statement for Oragenics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.4 | -15.7 | -14.3 | -20.7 | -10.6 |
| Depreciation | |||||
| Non-Cash Items | 9.39 | 1.69 | 0.731 | 11.3 | 0.516 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.037 | 0.512 | -1.72 | 2.02 | 1.45 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -17 | -13.5 | -15.2 | -7.29 | -8.6 |
| Capital Expenditures | 0 | -0.044 | -0.128 | -1 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | 0.012 | 0.064 | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | 0 | -0.044 | -0.116 | -0.936 | — |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16.3 | 23.1 | -0.495 | 0.284 | 5.98 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.628 | 9.63 | -15.8 | -7.94 | -2.62 |